Melanoma Immunotherapy Most Effective in Older Patients

A well-aged tumor microenvironment, of the sort found in older cancer patients, may be more susceptible to checkpoint blockade, a form of cancer immunotherapy. This finding, reported by scientists based at the Wistar Institute, suggests that “aging” the tumor microenvironment—by depleting it of immune suppressive T cells—could improve immunotherapy response rates for younger cancer patients.With each decade of life, the Wistar team discovered, the likelihood of progressio